Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, accelerating its inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of venous thromboembolism (deep vein thrombosis, pulmonary embolism),Treatment of atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, non-ST-elevation myocardial infarction),Prevention of clotting in arterial and cardiac surgery, hemodialysis, and extracorporeal circuits
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
5,000 units IV bolus, followed by continuous IV infusion of 18 units/kg/hr (initial based on actual body weight) for treatment of venous thromboembolism; or 5,000 units subcutaneously every 8-12 hours for prophylaxis of deep vein thrombosis. Titrate to a PTT 1.5-2.5 times control.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal half-life: 1-2 hours (dose-dependent; mean 1.5 hours). Clinical context: Prolonged in hepatic/renal insufficiency; obesity (increased Vd). IV bolus: 30-60 min; continuous infusion: 1-2 hours.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin undergoes desulfation and partial depolymerization in the liver and reticuloendothelial system; primarily cleared by the kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: 40% as unchanged drug; reticuloendothelial system (liver, spleen): 60% metabolized to low molecular weight forms, then renally eliminated.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
High, >95% bound to antithrombin III, albumin, and other plasma proteins.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.04-0.06 L/kg (confined to plasma; does not cross placenta). Clinical meaning: Low Vd reflects limited extravascular distribution; predominantly intravascular.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
SC: 20-30% (due to first-pass hepatic metabolism and local inactivation).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No standard dose adjustment for GFR; however, close monitoring of a PTT and for bleeding is recommended in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment based on Child-Pugh class; use with caution in hepatic disease due to decreased clearance and increased risk of bleeding. Monitor a PTT and clinical response.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Loading dose: 75-100 units/kg IV over 10 minutes. Maintenance infusion: For age ≤1 year: 28 units/kg/hr; age >1 year: 20 units/kg/hr; adjust to achieve a PTT of 60-85 seconds or anti-Xa level of 0.3-0.7 units/m L.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Increased risk of bleeding; consider lower initial infusion rates (e.g., 12-15 units/kg/hr) and more frequent a PTT monitoring. Use caution due to age-related renal function decline and concurrent medications.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients anticoagulated with heparin who receive neuraxial anesthesia or undergo spinal puncture. Risk is increased by indwelling epidural catheters, concomitant use of drugs affecting hemostasis (e.g., NSAIDs, platelet inhibitors, anticoagulants), traumatic or repeated puncture. Monitor for signs/symptoms of neurological impairment.
None
Risk of hemorrhage, especially in patients with bleeding disorders, recent surgery, or concurrent use of antiplatelet agents or anticoagulants. Monitor platelet counts for heparin-induced thrombocytopenia (HIT). May cause hyperkalemia by suppressing aldosterone secretion. Use with caution in hepatic or renal impairment. Avoid intramuscular injection.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to heparin or pork products, history of heparin-induced thrombocytopenia (HIT), active major bleeding (except when due to disseminated intravascular coagulation), severe thrombocytopenia, inability to perform adequate coagulation monitoring.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. Heparin is administered parenterally and does not interact with dietary components. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin activity.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Heparin does not cross the placenta; no known teratogenic risk. First trimester: No increased risk of major malformations. Second/third trimesters: Risk of maternal hemorrhage, placental abruption, or preterm labor if anticoagulation is excessive. No direct fetal toxicity.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to high molecular weight and poor oral bioavailability. Considered safe during breastfeeding; M/P ratio is not applicable (undetectable in milk).
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy increases volume of distribution and renal clearance, possibly requiring higher doses (e.g., 10-20% increase) to achieve therapeutic a PTT. Monitor a PTT frequently (e.g., weekly or with dose changes) and adjust accordingly. No specific dose conversion for IV to subcutaneous; use weight-based dosing.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Heparin flushes (5000 U/m L) are used for catheter patency only; do not use therapeutic dosing. Verify concentration before administration. Flush volume should match catheter lumen volume. Monitor for bleeding risk in patients with thrombocytopenia or coagulation disorders. Use preservative-free formulation in neonates.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is used to keep your IV line or catheter from clotting.,It contains heparin and will be given by a healthcare professional.,Tell your doctor if you have a history of heparin-induced thrombocytopenia (HIT) or if you take blood thinners like warfarin.,Report any unusual bleeding, bruising, or pain at the IV site immediately.,You may need regular blood tests to monitor your platelet count.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Heparin binds to antithrombin III, accelerating its inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is: 5,000 units IV bolus, followed by continuous IV infusion of 18 units/kg/hr (initial based on actual body weight) for treatment of venous thromboembolism; or 5,000 units subcutaneously every 8-12 hours for prophylaxis of deep vein thrombosis. Titrate to a PTT 1.5-2.5 times control.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Heparin does not cross the placenta; no known teratogenic risk. First trimester: No increased risk of major malformations. Second/third trimesters: Risk of maternal hemorrhage, pla. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.